Hypomethylating agent: treatment of the LGLL cell line MOTN-1 cells with 5-azacytidine resulted in decreased IL-15 expression; implicating IL-15 promoter hypermethylation as a key driver of IL-15 induced LGLL. Decreasing IL-15 production by demethylating the promoter is being explored in a phase I clinical trial (NCT05141682) evaluating an oral 5-azacytidine formulation (CC-486) in patients with LGLL. The gene discussed is IL15; the disease is T-cell large granular lymphocyte leukemia.